Skip to main content

Patricia Bogdanov Baruj

Institutions of which they are part

Postdoctoral researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Patricia Bogdanov Baruj

Institutions of which they are part

Postdoctoral researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Nuevas perspectivas en mediadores inflamatorios en la patogenia del edema macular diabético: implicaciones terapéuticas

IP: Cristina Hernández Pascual
Collaborators: Hugo Ramos Abellan, Patricia Bogdanov Baruj
Funding agency: Instituto de Salud Carlos III
Funding: 149132.5
Reference: PI19/01215
Duration: 01/01/2020 - 31/12/2022

Unraveling the retinal and brain mediators of diabetes-induced neurodegeneration

IP: Rafael Simó Canonge
Collaborators: Santiago Ramon y Cajal Agüeras, Joan Montaner Villalonga, Lorena Ramos Pérez, Hugo Ramos Abellan, Patricia Bogdanov Baruj
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 242000
Reference: PID2019-104225RB-I00
Duration: 01/06/2020 - 31/05/2023

Ministerio de Ciencia

Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia

IP: Rafael Simó Canonge
Collaborators: Marina Jimenez Iglesias, Cristina Hernández Pascual, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Patricia Bogdanov Baruj, Andreea Ciudin Mihai, Ferran Casals Riera, Itziar Busquets Saez, Maddalen Zufiaurre Seijo, Enrique Franky Vargas, José Raul Herance Camacho, Ingrid Balcells Ortega, Marco Inzitari
Funding agency: EUROPEAN COMMISSION
Funding: 974782.7
Reference: RECOGNISED_H2020SC1BHC2019
Duration: 01/01/2020 - 31/12/2024

Administración tópica de agonistas del receptor de GLP-1: una nueva estrategia para el tratamiento de la retinopatía deiabética

IP: Rafael Simó Canonge
Collaborators: Patricia Bogdanov Baruj
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 266200
Reference: SAF2016-77784-R
Duration: 30/12/2016 - 29/12/2019

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Josep Sanjose Puig

Josep Sanjose Puig

Tècnic/a Superior Recerca
Clinical Research Development Directorate
Read more
Jordi Gómez i Prat

Jordi Gómez i Prat

Infectious Diseases
Read more
Marta Rebull Santamaria

Marta Rebull Santamaria

Research technician
Biomedical Research in Gynaecology
Read more
Marc Aguilar García

Marc Aguilar García

Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.